archive-com.com » COM » K » KURMANNPARTNERS.COM

Total: 16

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Mergers & Acquisitions in Pharma and MedTech - Kurmann Partners AG
    mixing archetypes focusing on the appropriate model will be a fundamental M A driver Turning to the implications for Pharma manufacturing we point out that Pharma companies with the notable exception of generic drug providers are realizing that in house manufacturing is not a core competence Outsourcing and in particular divestments of manufacturing units combined with service contracts to buyer operators with certain technology specializations are increasing Get your own copy of the presentation via download here KP assists Tillotts Pharma AG in the Tillotts Pharma AG the European affiliate of the Japanese Zeria Pharmaceutical has acquired the global rights for Entocort budesonide outside the more KP assists Tillotts Pharma AG in the acquisition of Entocort from AstraZeneca Tillotts Pharma AG the European affiliate of the Japanese Zeria Pharmaceutical has acquired the global rights for Entocort budesonide outside the U S from AstraZeneca for the amount of US 215 million Kurmann Partners has been mandated by Tillotts Pharma to identify companies or strong brands which meet their strategic growth objectives Entocort a gastroenterology medicine for patients with mild to moderate Crohn s disease and ulcerative colitis represents such a fit as it strengthens Tillotts position as a leading European specialist in the area of gastroenterology Kurmann Partners has assisted Tillotts throughout the entire acquisition process and we are very pleased that the transaction could be concluded successfully Global Pharma Biotech M A report 2015 The 2015 edition of the Global Pharma Biotech M A Report features A global overview about the record breaking M A activity in the Pharma Biotech more Global Pharma Biotech M A report 2015 The 2015 edition of the Global Pharma Biotech M A Report features A global overview about the record breaking M A activity in the Pharma Biotech industry in 2014 download here Regional trend s and deal drivers USA Western Europe CEE China Latin America download here M A in Pharma manufacturing CMO consolidation and disposal of manufacturing sites by Big Pharma download here Tax inversions by US Pharma companies through acquisitions one of the major deal and valuation drivers in the past years download here Poster the molecular structure of the top 30 drugs by sales download here Download the full report here Sale of Novartis Manufacturing Facility Kurmann Partners advised Novartis on the divestment of its Taboa da Serra plant as a going concern to União Quimica one of the larger national more Sale of Novartis Manufacturing Facility Taboa da Serra Brazil to União Química Kurmann Partners advised Novartis on the divestment of its Taboa da Serra plant as a going concern to União Quimica one of the larger national pharmaceutical enterprises in Brazil Kurmann Partners was involved throughout the entire transaction including deal structure carve out of the operation identification and approach of candidate buyers and negotiation of terms and conditions of the deal Sale of Hameln Pharma to the Siegfried Kurmann Partners led the sale of the sterile filling business of the Hameln Group Hameln Pharma consisting of Hameln Pharma GmbH Hameln RDS and more Sale of Hameln Pharma to the Siegfried Group Kurmann Partners led the sale of the sterile filling business of the Hameln Group Hameln Pharma consisting of Hameln Pharma GmbH Hameln RDS and Hameln Real Estate to the Siegfried Group See details here Acquisition of the complete product Kurmann Partners assisted Grunenthal Group in acquiring the complete product portfolio of Biogen Laboratorios de Colombia S A The transaction more Acquisition of the complete product portfolio of Biogen Laboratorios by the Grunenthal Group Kurmann Partners assisted Grunenthal Group in acquiring the complete product portfolio of Biogen Laboratorios de Colombia S A The transaction implied a complex carve out of the product portfolio including a challenging tech transfer process to ensure future production of the broad portfolio The German pharmaceutical corporation Grunenthal is a leading innovator in the pain segment and has been seeking to strengthen its Latin American franchise by acquiring prescription drug businesses to complement its general medical portfolio in the region Sale of Spirig Pharma AG Dermatology Spirig Pharma AG is the largest and best known dermatology company in Switerland and has subsidiaries and strong market positions in Germany Austria more Sale of Spirig Pharma AG Dermatology to Galderma SA Spirig Pharma AG is the largest and best known dermatology company in Switerland and has subsidiaries and strong market positions in Germany Austria Czech Republic Slovakia and France The best known brands owned by Spirig are Daylong sun protection Excipial dry skin Tretinac acne and Actinica prevention of Actinic Keratosis Due to the ongoing and consolidation process in the Pharmaceutical industry the owners and the management on Spirig decided to re position the company and have it integrated into a larger organization We led an auction with a small number of potential strategic buyers which were pre selected applying stringent criteria Within only six months after their decision to sell the owners could seal the sale to Galderma S A an ideal new owner Galderma a joint venture of Nestlé and L Oreal with headquarters in Lausanne CHF 1 6bn revenues and 4 000 staff is the globally leading dermatology company Galderma intends to build a global Center of Excellence in Egerkingen and will continue to invest into the company Acquisition of James Brown Pharma by Grupo Farma GF Caracas has acquired the pharmaceutical product portfolio of James Brown Pharma Ecuador as per November 01 2012 price more Acquisition of James Brown Pharma by Grupo Farma Grupo Farma GF Caracas has acquired the pharmaceutical product portfolio of James Brown Pharma Ecuador as per November 01 2012 price undisclosed Kurmann Partners has been mandated by GF to identify targets which fit the strategic objectives of GF and to advise GF on the acquisition transaction Further acquisitions of strong brands and or pharmaceutical businesses in Colombia Peru and Ecuador are under analysis Sale of CAS Clean Air Service AG to Spectris plc Kurmann Partners led the selling process for the Switzerland based CAS CAS is a

    Original URL path: http://www.kurmannpartners.com/ (2016-04-26)
    Open archived version from archive

  • Mergers & Acquisitions - Kurmann Partners AG
    Corporate Finance of the Migros Group we implemented the Due Diligence and the contract negotiations for a majority stake in Hallam Acquisition of Polymer Tec GmbH by Sekisui Alvea a subsidiary of Sekisui Chemical Corp Strategic acquisition of new technology platform Sekisui Chemical Corp Tokyo Japan is the leading producer of physically cross linked polyolefin foams Its European subsidiary Sekisui Alveo had deciced to expand its product portfolio with non cross linked polyolefin foams NXPOs When NXPO producer Polymer Tec GmbH Bad Sobernheim Germany entered a sales process we critically reviewed the strategic rationale valuated the synergy potentials and led all stages of the transaction process including coordination of all other consultants involved Strategic alliances and acquisitions by Mepha Development and execution of external growth strategy Mepha is the leader for generic drugs in Switzerland with a market share of more than 35 To secure further growth Mepha wanted to expand into new but related fields by acquisitions and strategic alliances Jointly with the management we developed the acquisition strategy coached the laying of the of the pertaining organizational foundations and supported Mepha in the establishment of multiple strategic alliances and acquisitions in Switzerland and abroad Co development and exclusive licence agreement of M et P Patent AG with Urigen Pharmaceuticals Inc Co development and exclusive license agreement for a phase II drug candidate M et P Patent AG Stans Schweiz required capital to continue the development of its portfolio of highly promising drug candidates We developed comprehensive information materials about the projects and closely advised the client during complex negotiations with Urigen Pharmaceuticals Inc The result was a co development and licensing agreement for one of the drug candidates which provides M et P Patent AG with substantial milestone and royalty payments which it can invest into the development of further pipeline products Sale Acquisition Other All Sale of CAS Clean Air Service AG to Spectris plc Kurmann Partners led the selling process for the Switzerland based CAS CAS is a leading more Sale of CAS Clean Air Service AG to Spectris plc Kurmann Partners led the selling process for the Switzerland based CAS CAS is a leading specialist for clean room measuring services and certification in the German speaking markets with a particular focus on the pharmaceutical industry and health care institutions The public Spectris plc based in UK is a leading supplier of productivity enhancing instrumentation and controls CAS will be integrated into Particle Measuring Systems PMS within Spectris Materials Analysis segment all CAS employees will be taken over Kurmann Partners supported the sellers from elaborating the selling documentation to structuring the transaction global search of suitable buyers soliciting offers organizing and managing the Virtual Data Room negotiating the Share Purchase Agreement up to signing and closing of the transaction KP advises on the sale of an Alcon manufacturing site to Recipharm KP advised Alcon a Novartis Division on a strategic collaboration with Swedish CDMO Recipharm AB more KP advises on the sale of an Alcon manufacturing site to Recipharm KP advised Alcon a Novartis Division on a strategic collaboration with Swedish CDMO Recipharm AB The resulting transaction combines a long term supply agreement for a range of ophthalmic products and the sale of the Alcon manufacturing site in Kaysersberg France to Recipharm KP assists Tillotts Pharma AG in the acquisition of Entocort from AstraZeneca Tillotts Pharma AG the European affiliate of the Japanese Zeria Pharmaceutical has acquired the more KP assists Tillotts Pharma AG in the acquisition of Entocort from AstraZeneca Tillotts Pharma AG the European affiliate of the Japanese Zeria Pharmaceutical has acquired the global rights for Entocort budesonide outside the U S from AstraZeneca for the amount of US 215 million Kurmann Partners has been mandated by Tillotts Pharma to identify companies or strong brands which meet their strategic growth objectives Entocort a gastroenterology medicine for patients with mild to moderate Crohn s disease and ulcerative colitis represents such a fit as it strengthens Tillotts position as a leading European specialist in the area of gastroenterology Kurmann Partners has assisted Tillotts throughout the entire acquisition process and we are very pleased that the transaction could be concluded successfully Sale of Novartis Manufacturing Facility Taboa da Serra Brazil to União Química Kurmann Partners advised Novartis on the divestment of its Taboa da Serra plant as a going concern more Sale of Novartis Manufacturing Facility Taboa da Serra Brazil to União Química Kurmann Partners advised Novartis on the divestment of its Taboa da Serra plant as a going concern to União Quimica one of the larger national pharmaceutical enterprises in Brazil Kurmann Partners was involved throughout the entire transaction including deal structure carve out of the operation identification and approach of candidate buyers and negotiation of terms and conditions of the deal Sale of Hameln Pharma to the Siegfried Group Kurmann Partners led the sale of the sterile filling business of the Hameln Group Hameln Pharma more Sale of Hameln Pharma to the Siegfried Group Kurmann Partners led the sale of the sterile filling business of the Hameln Group Hameln Pharma consisting of Hameln Pharma GmbH Hameln RDS and Hameln Real Estate to the Siegfried Group See details here Acquisition of the complete product portfolio of Biogen Laboratorios by the Grunenthal Group Kurmann Partners assisted Grunenthal Group in acquiring the complete product portfolio of Biogen more Acquisition of the complete product portfolio of Biogen Laboratorios by the Grunenthal Group Kurmann Partners assisted Grunenthal Group in acquiring the complete product portfolio of Biogen Laboratorios de Colombia S A The transaction implied a complex carve out of the product portfolio including a challenging tech transfer process to ensure future production of the broad portfolio The German pharmaceutical corporation Grunenthal is a leading innovator in the pain segment and has been seeking to strengthen its Latin American franchise by acquiring prescription drug businesses to complement its general medical portfolio in the region Sale of Spirig Pharma AG Dermatology to Galderma SA Spirig Pharma AG is the largest and best

    Original URL path: http://www.kurmannpartners.com/mergers-acquisitions/ (2016-04-26)
    Open archived version from archive

  • Global Reach - Kurmann Partners AG
    around the world Naturally we support our clients wherever they wish to do business Our partner team has a wealth of industry and international senior management experience We complement our international experience and contacts with industry specialists our Senior Advisors who work with us on a contractual base on selected mandates As a member of IMAP the largest organization of independent M A firms we can activate qualified transaction support

    Original URL path: http://www.kurmannpartners.com/global-reach/ (2016-04-26)
    Open archived version from archive

  • Research - Kurmann Partners AG
    China Sailing in Choppy Waters Read in this report from InterChina Consulting IMAP China about crucial implications of China s China Sailing in Choppy Waters Read in this report from InterChina Consulting IMAP China about crucial implications of China s political reforms for the country s business environment and how international companies may handle this new environment Download here M A in China A Corporate Survey by InterChina M A transactions in China are around 5 of global activity while two thirds of all transactions are M A in China A Corporate Survey by InterChina M A transactions in China are around 5 of global activity while two thirds of all transactions are domestic This survey by InterChina Consulting IMAP China presents the view on M A in China by some of the leading multinational companies that are well established in China Download here Strategies for the China Oncology Market This report from InterChina Consulting IMAP China provides insights and strategies for Strategies for the China Oncology Market This report from InterChina Consulting IMAP China provides insights and strategies for pharmaceutical companies in the rapidly growing Chinese oncology market Download here Global Pharma Biotech M A Report 2013 IMAP s Global Pharma Biotech M A Report 2013 contains regional reviews and highlights on M A Global Pharma Biotech M A Report 2013 IMAP s Global Pharma Biotech M A Report 2013 contains regional reviews and highlights on M A trends in the industry Download here Full Version 9 MB Light Version 1 MB CEIBS Business in China Survey 2013 This InterChina IMAP China report based on a survey from CEIBS documents the perceived business CEIBS Business in China Survey 2013 This InterChina IMAP China report based on a survey from CEIBS documents the perceived business environment of Chinese and foreign companies in China Read about main challenges success factors and future oulook of these companies Download here Investment Opportunities in China s Eldercare Industry China s aging society offers interesting investment opportunities for the healthcare sector This Investment Opportunities in China s Eldercare Industry China s aging society offers interesting investment opportunities for the healthcare sector This report from InterChina IMAP China provides an overview of today s Chinese eldercare industry its policy environment and its market outlook Download here Vitamins Minerals Supplements M A Summary Demand for VMS doesn t just come from consumers corporates and private equity houses have been Vitamins Minerals Supplements M A Summary Demand for VMS doesn t just come from consumers corporates and private equity houses have been actively pursuing M A in the sector too Learn more in the report from Clearwater IMAP UK Download here Global Pharma Biotech M A Report 2012 Review of 2011 M A deals including Gilead Pharmasset anatomy of a billion dollar R D deal And Global Pharma Biotech M A Report 2012 Review of 2011 M A deals including Gilead Pharmasset anatomy of a billion dollar R D deal And will Pharma grow in mature markets until

    Original URL path: http://www.kurmannpartners.com/research/ (2016-04-26)
    Open archived version from archive

  • Team - Kurmann Partners AG
    Molecular Biotechnology from the University of Heidelberg During his academic education he worked in the pre clinical research department of Dr Willmar Schwabe GmbH and as a finance intern at Novartis Pharma Before joining Kurmann Partners he worked for Novartis Pharma in the Global TechOps department as Business Planner and Analyst Experts Gert Diederich Senior Advisor Gert Diederich Senior Advisor Gert Diederich holds a Master s degree in Business and Engineering from the Technical University Darmstadt During 30 years he held several senior management positions in the Pharma industry At Degussa he was Group Audit Manager Division Controller CFO of the Brazilian subsidiary in years of hyperinflation Director Controlling of the affiliate Arzneimittelwerk Dresden AWD after the German Reunification and Vice President Controlling of ASTA Medica group controlling affiliates strategy devilment and implementation project leader integration of AWD internal consulting outsourcing M A He was also Vice President Accounting and Controlling Management affiliates process optimization growth strategy at Boehringer Ingelheim CFO for the Holding of the Hameln group and CEO of a CMO for parenteral drugs growth strategy optimization of processes costs and capital Thomas Dressendörfer Senior Advisor Thomas Dressendörfer Senior Advisor Owner of DCS Consulting Thomas Dressendörfer has had a progressive career in finance holding key senior finance positions CFO of major business units regions in several international companies including Straumann Uster Technologies Randstad The Nielsen Company Procter Gamble and Baumüller His career has thus brought him through the Healthcare and Consumer Products industry as well as the Personnel Services Market Intelligence and Mechanical Engineering sectors in various countries 2008 he moved to Switzerland and first joined Uster Technologies Ltd a publically traded company in the cotton quality testing industry where he has been for 4 years Chief Financial Officer and a Member of the Executive Committee In the last 4 years he has been Chief Financial Officer and a Member of the Executive Committee with Straumann a publically traded company in the dental implant industry where he has contributed significantly to the past years success Since the beginning of 2016 he started up his own company DCS Consulting with focus on support for high value complex business project and restructuring turnaround He brings along as well extensive experience in M A transactions Thomas is a German citizen with a wide cultural background in addition to his international professional experience he grew up abroad and then studied in Germany gaining a Masters in Business Administration and Economics from the University of Erlangen Nürnberg Alfredo Granai Senior Advisor Alfredo Granai Senior Advisor Alfredo Granai is a Global Senior Leader with proven success in building and developing business for large and midsize life science corporations through market expansion startup operations and acquisitions For Depuy Synthes at Johnson Johnson he was the President of Latin America with full P L responsibility within 2012 and 2016 Before this assignment he was President of Latin America for Synthes within 2001 and 2012 with full P L responsibility including infrastructure and operations Prior to joining

    Original URL path: http://www.kurmannpartners.com/team/ (2016-04-26)
    Open archived version from archive

  • News - Kurmann Partners AG
    exception of generic drug providers are realizing that in house manufacturing is not a core competence Outsourcing and in particular divestments of manufacturing units combined with service contracts to buyer operators with certain technology specializations are increasing Get your own copy of the presentation via download here KP assists Tillotts in the acquisition of Entocort We are pleased to inform that Tillotts Pharma AG the European affiliate of the Japanese Zeria KP assists Tillotts in the acquisition of Entocort We are pleased to inform that Tillotts Pharma AG the European affiliate of the Japanese Zeria Pharmaceutical has acquired the global rights for Entocort budesonide outside the U S from AstraZeneca for the amount of US 215 million Kurmann Partners has been mandated by Tillotts Pharma to identify companies or strong brands which meet their strategic growth objectives Entocort a gastroenterology medicine for patients with mild to moderate Crohn s disease and ulcerative colitis represents such a fit as it strengthens Tillotts position as a leading European specialist in the area of gastroenterology Kurmann Partners has assisted Tillotts throughout the entire acquisition process and we are very pleased that the transaction could be concluded successfully Michel Le Bars becomes Equity Partner We are pleased to announce that Michel Le Bars has joined Peter Degen and Christoph Bieri as Michel Le Bars becomes Equity Partner We are pleased to announce that Michel Le Bars has joined Peter Degen and Christoph Bieri as shareholders of Kurmann Partners Prior to joining Kurmann Partners beginning of 2014 Michel held several positions at Merck Co MSD in Europe contributing to the business transformation and Emerging Markets growth strategy In his latest position he was driving the Business Development across the Europe Middle East and Africa regions Prior to Merck Michel was leading the transformation process of the global manufacturing footprint of Alcan Packaging now Albéa He started his career at Total as a drilling manager of Oil Gas exploration projects Michel holds two diplomas in engineering and an MBA of HEC Paris He is fluent in French English German Spanish and Portuguese Find his full professional profile here KP advises on Novartis sale of their plant in Taboa da Serra Brazil We are pleased to announce the closing of the divestment of Novartis Taboa da Serra plant as a KP advises on Novartis sale of their plant in Taboa da Serra Brazil We are pleased to announce the closing of the divestment of Novartis Taboa da Serra plant as a going concern to União Quimica one of the larger national pharmaceutical enterprises in Brazil Kurmann Partners advised Novartis throughout the entire transaction including deal structure carve out of the operation identification and approach of candidate buyers and negotiation of terms and conditions of the deal Global Pharma Biotech M A report 2015 The 2015 edition of the Global Pharma Biotech M A Report features A global overview about the Global Pharma Biotech M A report 2015 The 2015 edition of the Global Pharma Biotech M A Report features A global overview about the record breaking M A activity in the Pharma Biotech industry in 2014 download here Regional trend s and deal drivers USA Western Europe CEE China Latin America download here M A in Pharma manufacturing CMO consolidation and disposal of manufacturing sites by Big Pharma download here Tax inversions by US Pharma companies through acquisitions one of the major deal and valuation drivers in the past years download here Poster the molecular structure of the top 30 drugs by sales download here Download the full report here KP supports sale of Hameln Pharma to Siegfried Group We are pleased to inform you that Hameln Group successfully completed the divestment of its sterile KP supports sale of Hameln Pharma to Siegfried Group We are pleased to inform you that Hameln Group successfully completed the divestment of its sterile filling business Hameln Pharma consisisting of Hameln Pharmaceuticals GmbH Hameln RDS und Hameln Real Estate The acquirer is Swiss based Siegfried Group Kurmann Partners advised Hameln Group throughout the process Hameln Pharma operates a state of the art plant for sterile filling of liquid Pharmaceuticals into ampoules and vials Employing 500 staff Hameln Pharma will generate approximately EUR 72m revenues in 2014 By selling to Siegfried Group Hameln Group transfers the sterile filling business to one of the globally leading providers of these services Siegfried will continue to employ all of Hameln Pharma s staff The Hameln Group with its remaining subsidiaries will in future focus on their worldwide business activities with their own brand of injectable pharmaceutical finished products Fall event 4 November 2014 M A as a core competence of the company The event will take place on November 4 2014 from 6 p m at Fall event 4 November 2014 M A as a core competence of the company The event will take place on November 4 2014 from 6 p m at the SIX Swiss Stock Exchange in Zurich and is completed with an aperitif The lectures will be held in German language The presentation materials will be partly in English Your registration is necessary because the number of participants is limited A participation fee of CHF 50 is provided in advance invoice Registration form Download des Program with brief profiles of key speakers Global Pharma Biotech M A Report 2014 IMAP releases the 2014 edition of the Global Pharma Biotech M A Report find details here Global Pharma Biotech M A Report 2014 IMAP releases the 2014 edition of the Global Pharma Biotech M A Report find details here MergerTalk January 2014 Our Newsletter MergerTalk can be downloaded here and contains inter alia Lead article Choppy MergerTalk January 2014 Our Newsletter MergerTalk can be downloaded here and contains inter alia Lead article Choppy Waters ahead in China Current projects search and sale items MergerTalk September 2013 Our Newsletter MergerTalk can be downloaded here an contains inter alia Lead article Sale of a MergerTalk September 2013 Our Newsletter MergerTalk can be downloaded here

    Original URL path: http://www.kurmannpartners.com/news/ (2016-04-26)
    Open archived version from archive

  • Contact - Kurmann Partners AG
    News Contact English Deutsch Contact Home Mergers Acquisitions Global Reach Research Team News Contact Kurmann Partners AG Elisabethenanlage 25 4051 Basel 41 58 261 90 50 mail kurmannpartners com 2016

    Original URL path: http://www.kurmannpartners.com/contact/ (2016-04-26)
    Open archived version from archive

  • Kurmann Partners DE - Kurmann Partners AG
    Recipharm AG beraten Die resultierende Transaktion kombiniert ein langfristiges Abkommen zur Herstellung eines Portfolios von Ophtalmologie Produkten und den Verkauf der Alcon Produktionsstätte in Kaysersberg Frankreich an Recipharm KP stellt 4 strategische Archetypen Kurmann Partners war zur CPhI 2015 in Madrid eingeladen um KP s neueste Insights zum Thema M A Treiber in der Pharmaindustrie vorzustellen Die more KP stellt 4 strategische Archetypen auf der CPhI vor Kurmann Partners war zur CPhI 2015 in Madrid eingeladen um KP s neueste Insights zum Thema M A Treiber in der Pharmaindustrie vorzustellen Die Pharma Industrie steht mehrfach unter Druck Die Investitionen für die Entwicklung neuer Wirkstoffe sind nur noch für grosse Unternehmen tragbar Gleichzeitig nimmt der Kostendruck im Gesundheitswesen und damit der Preisdruck für Medikamente stetig zu Die Industrie durchläuft daher umwälzende Veränderungen Wir glauben dass sich Pharma Firmen grundsätzlich für eine von vier Strategien oder strategischen Archetypen entscheiden müssen Entwickler Orginator Anbieter günstiger Kopien Generika Biosimilars Spezialist für bestimmte Ärztegruppen oder Anbieter von Produkten im Bereich Consumer Health Jeder Archetyp hat spezifische Rahmenbedingungen und seine eigene Wettbewerbdynamik Archetypen können nicht gemischt werden wobei es Überkreuzungen gibt Mehr Informationen zum Thema finden Sie hier KP s CPhI Präsentation Poster 4 Archetypen der Pharmaindustrie KP unterstützt Tillotts Pharma AG in der Tillotts Pharma AG die Europäische Tochter der Japanischen Zeria Pharmaceutical die globalen Rechte an Entocort budesonide von AstraZeneca für US more KP unterstützt Tillotts Pharma AG in der Akquisition von Entocort AstraZeneca Tillotts Pharma AG die Europäische Tochter der Japanischen Zeria Pharmaceutical die globalen Rechte an Entocort budesonide von AstraZeneca für US 215 Millionen erworben US Markt ausgenommen KP unterstützte Tillotts während des gesamten Akquisitionsprozesses Global Pharma Biotech M A report 2015 The 2015 edition of the Global Pharma Biotech M A Report features A global overview about the record breaking M A activity in the Pharma Biotech more Global Pharma Biotech M A report 2015 The 2015 edition of the Global Pharma Biotech M A Report features A global overview about the record breaking M A activity in the Pharma Biotech industry in 2014 download here Regional trend s and deal drivers USA Western Europe CEE China Latin America download here M A in Pharma manufacturing CMO consolidation and disposal of manufacturing sites by Big Pharma download here Tax inversions by US Pharma companies through acquisitions one of the major deal and valuation drivers in the past years download here Poster the molecular structure of the top 30 drugs by sales download here Download the full report here Verkauf der Novartis Produktionsstätte Kurmann Partners hat Novartis beim Verkauf ihrer Produktionsstätte in Taboa da Serra Brasilien an União Quimica eines der grössten brasilianischen more Verkauf der Novartis Produktionsstätte in Taboa da Serra Brasilien an União Química Kurmann Partners hat Novartis beim Verkauf ihrer Produktionsstätte in Taboa da Serra Brasilien an União Quimica eines der grössten brasilianischen Pharmaunternehmen beraten KP begleitete Novartis im gesamten Transaktionsprozess Dealstruktur Carve Out Suche nach geeigneten Käufern Einholen von Offerten Verhandeln des Kaufvertrage Verkauf von Hameln Pharma an die Kurmann Partners führte für die Hameln Group den Verkauf des Steril Abfüllungsgeschäftes Hameln Pharma mit den Tochtergesellschaften Hameln Pharma more Verkauf von Hameln Pharma an die Siegfried Gruppe Kurmann Partners führte für die Hameln Group den Verkauf des Steril Abfüllungsgeschäftes Hameln Pharma mit den Tochtergesellschaften Hameln Pharma GmbH Hameln RDS und Hameln Real Estate durch Acquisition of the complete product Kurmann Partners assisted Grunenthal Group in acquiring the complete product portfolio of Biogen Laboratorios de Colombia S A The transaction more Acquisition of the complete product portfolio of Biogen Laboratorios by the Grunenthal Group Kurmann Partners assisted Grunenthal Group in acquiring the complete product portfolio of Biogen Laboratorios de Colombia S A The transaction implied a complex carve out of the product portfolio including a challenging tech transfer process to ensure future production of the broad portfolio The German pharmaceutical corporation Grunenthal is a leading innovator in the pain segment and has been seeking to strengthen its Latin American franchise by acquiring prescription drug businesses to complement its general medical portfolio in the region Acquisition of James Brown Pharma by Grupo Farma GF Caracas has acquired the pharmaceutical product portfolio of James Brown Pharma Ecuador as per November 01 2012 price more Acquisition of James Brown Pharma by Grupo Farma Grupo Farma GF Caracas has acquired the pharmaceutical product portfolio of James Brown Pharma Ecuador as per November 01 2012 price undisclosed Kurmann Partners has been mandated by GF to identify targets which fit the strategic objectives of GF and to advise GF on the acquisition transaction Further acquisitions of strong brands and or pharmaceutical businesses in Colombia Peru and Ecuador are under analysis Verkauf der CAS Clean Air Service AG an Spectris plc Kurmann Partners führte für die Aktionäre der schweizerischen CAS deren Verkauf an die Spectris plc durch CAS ist der führende Spezialist für Reinraummessungen und zertifizierungen im deutschsprachigen Raum mit Schwerpunkten in der Pharmaindustrie und Gesundheitseinrichtungen Die in Grossbritannien beheimatete börsennotierte Spectris plc ist ein führender Hersteller von produktivitätssteigernden Instrumenten und Kontrollsystemen CAS wird in den Geschäftsbereich Particle Measuring Systems PMS innerhalb des Materials Analysis Segmentes von Spectris integriert alle CAS Mitarbeiter werden übernommen Kurmann Partners begleitete die Verkäufer von der Erstellung der Verkaufsunterlagen über die Strukturierung der Transaktion der weltweiten Suche nach geeigneten Käufern dem Einholen von Offerten dem Organisieren und Führen des Elektronischen Datenraumes dem Verhandeln des Kaufvertrages bis hin zum Signing und Closing der Transaktion Verkauf einer Alcon Produktionsstätte an Recipharm Kurmann Partners hat die Novartis Division hinsichtlich einer strategischen Kooperation mit der schwedischen CDMO Recipharm AG beraten Die resultierende Transaktion kombiniert ein langfristiges Abkommen zur Herstellung eines Portfolios von Ophtalmologie Produkten und den Verkauf der Alcon Produktionsstätte in Kaysersberg Frankreich an Recipharm KP unterstützt Tillotts Pharma AG in der Akquisition von Entocort AstraZeneca Tillotts Pharma AG die Europäische Tochter der Japanischen Zeria Pharmaceutical die globalen Rechte an Entocort budesonide von AstraZeneca für US 215 Millionen erworben US Markt ausgenommen KP unterstützte Tillotts während des gesamten Akquisitionsprozesses Verkauf der Novartis Produktionsstätte in Taboa

    Original URL path: http://www.kurmannpartners.com/de/ (2016-04-26)
    Open archived version from archive



  •